The future myeloma treatment landscape

Jesús San Miguel, MD, PhD, University of Navarra Clinic, Pamplona, Spain, talks on the future of myeloma treatment, highlighting research into precursor B-cells, the impact of the microenvironment on outcomes, circulating plasma cells, and resistance. Prof. San Miguel discusses the importance of tools for the identification of measurable residual disease (MRD) and early detection, and how these can be used to direct myeloma treatment. In addition, Prof. San Miguel gives an overview of the benefits of immunotherapies including antibodies and chimeric antigen receptor T-cell (CAR-T) therapies, and their potential use in earlier lines of treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.